Publications

Following is a list of selected publications:

• Gritsina G, Lin Z, Fong KW, Zhao JC, Lu X, Nelson PS, Corey E, Schiltz GE, Hussain M, Yu J. CXCR7 is up-regulated in neuroendocrine prostate cancer and promotes cancer growth through AURKA activation. J Clin Invest. 2023 Jun 22:e166248. doi: 10.1172/JCI166248. Online ahead of print. PMID: 37347559
• Lin Z, Agarwal S, Tan S, Shi H, Lu X, Tao Z, Dong X, Wu X, Zhao JC, Yu J. Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer. Oncogene. 2023 Jun;42(26):2126-2138. doi: 10.1038/s41388-023-02718-2. Epub 2023 May 17. PMID: 37198397
• Xie W, Agarwal S, Yu J. Ferroptosis: the vulnerability within a cancer monster. J Clin Invest. 2023 May 15;133(10):e170027. doi: 10.1172/JCI170027. PMID: 37183818 PMCID: PMC10178832. Commentary.
• Gritsina G, Yu J. CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene. 2023 Mar;42(11):785-792. doi: 10.1038/s41388-023-02597-7. Epub 2023 Feb 9. PMID: 36755058. Review.
• Fong KW, Zhao JC, Lu X, Kim J, Piunti A, Shilatifard A, Yu J. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Mol Cell.2022 Dec 01. PMID: 36476474 highlighted in news
• Wang X, Brea L, Lu X, Gritsina G, Park SH, Xie W, Zhao JC, Yu J. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene. 2022. Aug 5. doi: 10.1038/s41388-022-02423-6. Online ahead of print. PMID: 35931888 highlighted in news
• Lu X, Fong KW, Gritsina G, Wang F, Baca SC, Brea LT, Berchuck JE, Spisak S, Ross J, Morrissey C, Corey E, Chandel NS, Catalona WJ, Yang X, Freedman ML, Zhao JC, Yu J. HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nat Genet. 2022 April 25. PMID: 35468964 highlighted in news
• Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene.2021 August 04. PMID: 34349243
• Park SH, Fong KW, Kim J, Wang F, Lu X, Lee Y, Brea LT, Wadosky K, Guo C, Abdulkadir SA, Crispino JD, Fang D, Ntziachristos P, Liu X, Li X, Wan Y, Goodrich DW, Zhao JC, Yu J. Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science Advances. 2021 April 07. PMID: 33827814 highlighted in news
• Martin MC, Zeng G, Yu J, Schiltz GE. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer. J Med Chem.2020 Dec 24. PMID: 33283516
• R Vatapalli, V Sagar, Y Rodriguez, Zhao JC, K Unno, S Pamarthy, B Lysy, J Anker, H Han, Y A Yoo, M Truica, Z R Chalmers, F Giles, Yu J, D Chakravarti, B Carneiro, S A Abdulkadir. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature Communications. 2020 August 19. PMID: 32814769
• Zhu S, Zhao D, Li C, Li Q, Jiang W, Liu Q, Wang R, Fazli L, Li Y, Zhang L, Yi Y, Meng Q, Wang W, Wang G, Zhang M, Zu X, Zhao W, Deng T, Yu J, Dong X, Chen K, Cao Q. BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. Oncogene. 2019 August 28. PMID: 31462713
• Xu B, Song B, Lu X, Kim J, Hu M, Zhao JC, Yu J.Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression. Cell Research. 2019 July 19. PMID: 31324884
• Berger A, Brady NJ, Bareja R, Robinson BD, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 2019 July 01. PMID: 31260412
• Wang X, Brea LT, Yu J.Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy. Am J Clin Exp Urol. 2019 April 25. PMID: 31139703
• Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer. Cancer Res. 2019 April 05. PMID: 30952632
• Gritsina G, Gao WQ, Yu J.Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. Asian J Androl. 2019 March 29. PMID: 30950412
• Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Reports. 2018 Dec 04. PMID: 30517868 highlighted in news
• Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, Yang YA, Sridhar S, Lu X, Abdulkadir SA, Vessella RL, Morrissey C, Kuzel TM, Catalona WJ, Yang XJ, Yu J. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression. J Clin Invest. 2018 Dec 04. PMID: 30511964 highlighted in news
• Fong KW, Zhao JC, Song B, Zheng B, Yu J. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nat Commun. 2018 Nov 27. PMID: 30479348 highlighted in news
• Andrea E. Murmann, Yu J, Puneet Opa, Marcus E. Peter. Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer. Trends in Cancer. 2018 August
• Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, Liu Q, Wang R, Xia B, Zhao JC, Song G, Mi W, Wang RF, Shi X, Lam HM, Dong X, Yu J, Chen K, Cao Q. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nat Commun. 2018 Feb 5. PMID: 29402932
• Wang L, Song G, Zhang X, Feng T, Pan J, Chen W, Yang M, Bai X, Pang Y, Yu J, Han J, Han B. PADI2-mediated citrullination promotes prostate cancer progression. Cancer Research. 2017 August 17. PMID: 28819028
• Kim J, Jin H, Zhao JC, Yang YA, Li Y, Yang X, Dong X, Yu J. FOXA1 inhibits prostate cancer neuroendocrine differentiation.  Oncogene. 2017 March 20. PMID: 28319070
• Fong KW, Zhao JC, Kim J, Li S, Yang YA, Song B, Rittie L, Hu M, Yang X, Perbal B, Yu J. Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer. CancerRes. 2016 Nov 4. PMID: 27815387
• Kim JY, Yu J, Abdulkadir SA, Chakravarti D. KAT8 regulates androgen signaling in prostate cancer cells. Mol Endocrinol. 2016 June 07. PMID: 27257062
• Yang YA, Zhao JC, Fong KW, Kim J, Li S, Song C, Song B, Zheng B, He C, Yu J. FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function. Nucleic Acids Res. 2016 June 01. PMID: 27268279
• Zhao JC, Fong KW, Jin HJ, Yang YA, Kim J, Yu J. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene. 2016 Jan 11. PMID: 26751772 
• Zhang A, Zhao JC, Kim J, Fong KW, Yang YA, Chakravarti D, Mo YY, Yu J. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Reports. 2015 Aug.
• Shen S, Guo X, Yan H, Lu Y, Ji X, Li L, Liang T, Zhou D, Feng XH, Zhao JC, Yu J, Gong XG, Zhang L, Zhao B. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 2015 Aug 14. PMID: 26272168
• Xue XY, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC, Yu J. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2015 Sep 14. PMID: 26364613
• Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015 June
• Jin HJ, Zhao JC, Wu L, Kim J, Yu J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun. 2014 May 30. PMID: 24875621
• Yang YA, Kim J, Yu J. Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer. Appl Clin Genet. 2014 May 12. PMID: 24876790
• Kim J, Wu L, Zhao JC, Jin HJ, Yu J. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene.2013 Nov 4. [Epub ahead of print] PMID: 24186205
• Jin HJ, Kim J, Yu J. Androgen receptor genomic regulation. Translational Andrology and Urology. 2013;2(3):158-177
• Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Research. 2013 Aug 1. [Epub ahead of print] PMID: 23913826
• Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013 Apr 30. [Epub ahead of print] PMID: 23636686
• Jin HJ, Zhao JC, Ogden I, Bergan R, Yu J. Androgen-receptor independent function of FoxA1 in prostate cancer metastasis. Cancer Research. 2013 Mar 28. [Epub ahead of print] PMID: 23539448
• Wu L, Runkle C, Jin HJ, Yu JJ, Li J, Yang X, Kuzel T, Lee C, Yu J. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene. 2013 Jan 14. [Epub ahead of print] PMID: 23318417
• Kim J, Yu J. Interrogating genomic and epigenomic data to understand prostate cancer. BBA-Reviews on Cancer. 2012 Apr;1825(2):186-96. Epub 2012 Jan 3. PMID: 22240201
• Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012 Jan 1;26(1):54-68. PMID: 22215811
• Zhao JC, Yu JJ, Runkle C, Wu L, Hu M, Wu D, Liu JS, Wang Q, Qin ZS, Yu J. Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res. 2012 Feb;22(2):322-31. Epub 2011 Dec 16. PMID: 2217985554
• Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, Wu YM, Tomlins SA, Palanisamy N, Qin Z, Yu J, Maher CA, Varambally S, Chinnaiyan AM. Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell. 2011 Aug 16;20(2):187-99. PMID: 21840484
• Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011 Jul;21(7):1028-41. PMID: 21724842
• Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell. 2011 May 17;19(5):664-78. PMID: 21575865
• Corey SJ, Yu J. Cancer cell migration: when red light switched to green. Asian J Androl. 2011 Mar;13(2):177-8. Epub 2011 Jan 17. PMID: 21240294
• Yu J*, Cao Q, Yu JJ, Wu L, Dallol A, Li J, Chen G, Grasso C, Cao X, Lonigro RJ, Varambally S, Mehra R, Palanisamy N, Wu JY, Latif F, Chinnaiyan AM. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene. 2010 Jul 12. PMID: 20622896 *also a corresponding author.
• Qin ZS, Yu JJ, Shen J, Maher CA, Hu M, Kalyana-Sundaram S, Yu J, Chinnaiyan AM. HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics. 2010 Jul 2;11(1):369. PMID: 20598134
• Yu J, Yu JJ, Mani RS, Cao Q, Brenner CJ, Cao X, Wang GX, Wu L ...Qin ZS, Chinnaiyan AM. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell. 2010 May 18;17(5):443-54. Cover Article. PMID: 20478527
• Hu M, Yu J, Chinnaiyan AM, Qin Z. On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res. 2010 Jan 6. PMID: 20056654
• Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beoukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23;138(2):245-56. PMID: 19632176
• Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. PMID: 19212411
• Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science. 2008 Nov 13. PMID: 19008416
• Cao Q, Yu J, Tomlins SA, Mehra R, Dhanasekaran SM, Laxman B, Cao X, Yu JJ, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E_cadherin by the Polycomb group protein EZH2 in Cancer. Oncogene. 2008 Sep 22. PMID: 18806826
• Han B, Mehra R, Dhanasekaran S, Yu J, Lonigro B, Wang X, Laxman B, LeBlanc M, Wang L, Menon A, Tsodikov A, Shah RB, Palanisamy N, Tomlins SA, Chinnaiyan AM. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008 Sep 15;68(18):7629-37. PMID: 18794152
• Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008 Feb; 10(2):177-188. PMID: 18283340
• Yu JJ*, Yu J*, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, Lippman ME. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia. 2008 Jan;10(1):79-88. PMID: 18231641 *Co-authors with equal contribution
• Yu J, Yu JJ, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007;67(22):10657-63. Cover Article. PMID: 18006806
• Yu J, Cao Q, Mehra R, Laxman B, Yu JJ, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007; 12 (5). Featured Article. PMID: 17996646
• Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007 Aug 2;448(7153):595-9. PMID: 17671502
• Yu JJ, Yu J, Almal AA, Dhanasekaran SM, Ghosh D, Worzel WP, Chinnaiyan AM. Feature selection and molecular classification of cancer using genetic programming. Neoplasia. 2007; 9(4):292-303. PMID: 17460773
• Chen G. Wang X, Yu JJ, Varambally S, Yu J, Thomas DG, Chinnaiyan AM. Autoantibody Profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res. 2007; 67(7):3461-7. PMID: 17409457
• Yu J, He S, Friedman JS, Mears AJ, Ghosh D, Hicks D, Swaroop A. Altered expression of genes of the Bmp/Smad and Wnt/Ca2+ signaling pathways in the cone-only Nrl-knockout mouse retina, revealed by gene profiling using custom cDNA microarrays. J Biol Chem. 2004 Oct 1;279(40):42211-20. PMID: 15292180
• Yu J, Farjo R, MacNee SP, Baehr W, Stambolian DE, Swaroop A. Annotation and analysis of 10,000 expressed sequence tags from developing mouse eye and adult retina. Genome Biol. 2003;4(10):R65. PMID: 14519200
• Yu J, Othman MI, Farjo R, Zareparsi S, MacNee SP, Yoshida S, Swaroop A. Evaluation and optimization of procedures for target labeling and hybridization of cDNA microarrays. Mol. Vis. 2002 Apr 26;8:130-7. PMID: 12011805
• Farjo R*, Yu J*, Othman MI, Yoshida S, Sheth S, Baehr W, Swaroop A. Mouse eye gene microarrays for investigating ocular development and disease. Vision Res. 2002 Feb;42(4):463-70. PMID: 11853762 *Co-authors with equal contribution.